Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial.
Fiche publication
Date publication
mai 2023
Journal
JHEP reports : innovation in hepatology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BRONOWICKI Jean-Pierre
Tous les auteurs :
Seidensticker M, Öcal O, Schütte K, Malfertheiner P, Berg T, Loewe C, Klümpen HJ, van Delden O, Ümütlü MR, Ben Khaled N, de Toni EN, Seidensticker R, Aghdassi A, Tran A, Bronowicki JP, Peynircioglu B, Sangro B, Pech M, Ricke J
Lien Pubmed
Résumé
The aim of the study was to evaluate the efficacy and safety of adjuvant sorafenib treatment compared with placebo in patients with hepatocellular carcinoma who underwent local ablation.
Mots clés
Adjuvant, BCLC, Barcelona Clinic Liver Cancer, CONSORT, Consolidated Standards of Reporting Trials, CT, computed tomography, ECOG PS, Eastern Cooperative Oncology Group Performance Status, HCC, hepatocellular carcinoma, HR, hazard ratio, Hepatocellular carcinoma, ITT, intention-to-treat, Local ablation, MRI, magnetic resonance imaging, MWA, microwave ablation, PP, per protocol, RFA, radiofrequency ablation, RFS, relapse-free survival, SIRT, selective internal radiation therapy, SORAMIC, SORAfenib in combination with local MICro-therapy guided by gadolinium-EOB-DTPA-enhanced MRI, Sorafenib, TTR, time-to-recurrence, Time-to-recurrence
Référence
JHEP Rep. 2023 05;5(5):100699